TENAX THERAPEUTICS, INC. Passive Investment Disclosure (>5%)
Morgan Stanley reports beneficial ownership of 596,376 shares of Tenax Therapeutics, Inc. common stock, representing 9.6% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Morgan Stanley reports beneficial ownership of 596,376 shares of Tenax Therapeutics, Inc. common stock, representing 9.6% of the class. These shares are held with shared voting power over 592,316 shares and shared dispositive power over 596,376 shares.
Morgan Stanley Capital Services LLC reports beneficial ownership of 592,316 shares, or 9.5% of the common stock class, all with shared voting and dispositive power. The firms state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tenax.
AI-generated analysis. How Rhea-AI works. Not financial advice.